YouTube Facebook LinkedIn Google+ Twitter Xingrss  

Expensive Gene Therapy Approved in Europe


November 5, 2012 | Europe has approved an expensive gene therapy. Glybera treats the genetic disorder lipoprotein lipase deficiency (LPLD) and will cost around 1.2 million euros ($1.6 million) per patient. Reuters 
Click here to login and leave a comment.  

0 Comments

Add Comment

Text Only 2000 character limit

Page 1 of 1

For reprints and/or copyright permission, please contact  Jay Mulhern, (781) 972-1359, jmulhern@healthtech.com.